A leading genomics company with international reach is opening its first commercial location on the East Coast at Baltimore’s University Maryland BioPark.

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as VP, Clinical Development. Dr. Eisen is a translational medicine and clinical development specialist with over 20 years of experience in the biotech and pharma sectors.

For Jim Allison, cancer has always been at the back of his mind. He'd lost many family members to the disease, including his mother when he was young, and is himself a cancer survivor.

TruGenomix Combats PTSD Suicides

The University of Maryland (UM) BioPark and Wexford Science & Technology, LLC, today announced Illumina, Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems, as the newest tenant in the UM BioPark's 801 W. Baltimore St. building. The building is owned by Ventas, Inc., a life sciences real estate investment trust (REIT) and is part of Wexford's Knowledge Community development at the UM BioPark.

Watch this video on the Dutch biopharmaceutical industry in the Netherlands and get inspired by the Dutch. The perfect location to build your biopharmaceutical business. We open our doors for you!

Sea levels are rising, and that is sending more ocean water into streets, sewers and homes. For people who live and work in coastal communities, that means more otherwise-sunny days disrupted by flooding.

A tech company in Charlottesville is being recognized for its groundbreaking data that could help treat chronic illnesses.

New research done by AMPEL BioSolutions shows that a blood sample, when paired with its computer coding, can detect disease activity in patients who have lupus or other autoimmune diseases.

Maryland biotech Altimmune Inc. has reached an agreement to acquire California drug developer Spitfire Pharma Inc. in a move that sent the local company’s stock skyrocketing Tuesday.

Each of the seven startups received $150,000. To date in fiscal year 2019, $4.22 million in investments have been made through the Maryland Innovation Initiative program.

In honor of the new JLABS @ Washington, DC – a 32,000 square foot facility located on the new Children’s National Research and Innovation Campus from Johnson & Johnson Innovation, LLC in partnership with Children’s National Health System[1] (“Children’s National”) - Johnson & Johnson Innovation – JLABS announces the JLABS @ Washington, DC Children’s QuickFire Challenge.

Visionaries within the fields of pediatric oncology, pediatric surgery and influenza are invited to submit innovative ideas for a total of up to $150,000 in total grant funding; one year of residency at JLABS @ Washington, DC with the use of a bench, workstation, and access to the JLABS @ Washington, DC community; and mentorship from experts at the Johnson & Johnson Family of Companies.

Join Women In Bio-Capital Region for our annual summer networking picnic on Sunday, August 11th, 2019 from 10:00 a.m. to 1:00 p.m. Our chapter is providing the food and it will be brunch-style, under a lovely pavilion.

This is an open event, so please feel free to bring your family and friends for an opportunity to network and eat good food with your fellow WIB community. We look forward to seeing you at our upcoming annual summer networking picnic.

CHARLOTTESVILLE, VA – AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic diseases, like Lupus. Revealed in the peer-reviewed journal Nature’s Scientific Reports, the paper details our breakthrough machine learning approach to predict disease activity from gene data obtained from patient blood samples. The lab test, only a concept for the last few years, is now ready for development for practical use. AMPEL’s initial focus was Lupus, but the test can be used for many autoimmune or inflammatory diseases.

AMPEL’s innovative machine learning approach, which is now ready to be developed as a decision support biomarker blood test could greatly impact health care, by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatment more precisely. The application of our machine learning approach could assist pharmaceutical companies in drug development and clinical trials.

Do you have an innovative idea to help solve a health issue affecting moms and kids today? Here’s your chance to make it happen! The Maternal and Child Health Bureau (MCHB), part of the U.S. Health Resources and Services Administration (HRSA), invites you to participate in our four prize-awarded Challenges with a total prize purse of $1.5 million. These competitions seek low-cost, scalable, innovative solutions that improve the health of mothers and children across the U.S.

On behalf of Bio-Trac, Co-Founder and Director Mark Nardone received a Governor’s Citation for Bio-Trac’s 33 years of service to the scientific community, having provided hands-on training to over 17,000 scientists. At last night’s well attended Stem Cell BioPanel event at the Montgomery College Bioscience Education Center, Mr. Nardone was caught by surprise, not knowing this award was to take place. In a heartfelt address, he mentioned to the audience of scientists that it was exactly the 1 year anniversary of Dr. Roland M Nardone’s passing and how he would have been pleased by the honor but even more so to see a room full of research scientists attending an event to gain knowledge, insight and network among their peers.

American Gene Technologies (AGT), a leading gene and cell therapy company based in Rockville, MD, selected the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a new clinical site for its non-IND study, AGT-CS168, to collect clinical specimens from HIV positive individuals. AGT will use these materials to validate the patient-specific AGT103-T therapeutic manufacturing process. AGT expects AGT103-T will eliminate HIV from the body when infused back into the patient and will decrease or eliminate the need for lifelong antiretroviral treatment.

PHARMACEUTICAL giant GlaxoSmithKline (GSK) unveiled a new, fully automated continuous manufacturing facility and an expanded production building at its Jurong site on Friday, worth a total of S$130 million.

The Maryland Technology Development Corporation (TEDCO), Maryland’s economic engine for technology companies, announced its recent investments through the Maryland Innovation Initiative (MII). With the latest round of funding, MII’s funding count for FY19 includes 26 technology assessment grants and seven start-up investments for a total of $4.22 million. True to its technology agnostic funding history, this year the startups ranged from Cleantech to AI and Biotech.

Researchers at the Johns Hopkins Kimmel Cancer Center, the Greenberg Bladder Cancer Institute, the Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Brady Urological Institute, and the Center for Computational Genomics at Johns Hopkins have received a $3.2 million grant from the National Institutes of Health to study new treatment options for early-stage bladder cancer.

At the close of the 2019 BioHealth Capital Region Forum in April, Floreo Inc. was announced as the winner of the BioHealth Innovation’s 4th annual Crab Trap Competition and the $10,000 grand prize provided by WSGR. Floreo, Inc., which is “…using the power of virtual reality to deliver immersive, fun, and affordable lessons for children and adults with autism spectrum disorder (ASD)…”, was selected by the judges from a group of five finalists.

Access to capital has been an ongoing challenge for biohealth companies in the BioHealth Capital Region (BCHR) and throughout the Mid Atlantic, though recent investment data suggests that capital market access is improving. “PwC/CB Insights ranks the region fourth with $944.07 million in 44 deals and Jones Lang Lasalle tallies $1.1 billion, good enough for third,” stated Rich Bendis, CEO of BioHealth Innovation (BHI), in his keynote speech at the recent The National Cancer Institute (NCI) Technology Transfer Showcase. 

Just one week into 2019, the new year got off to the proverbial roaring start for biopharma mergers and acquisitions (M&A) with the announcement of two multi-billion-dollar deals valued at a total $82 billion—one of them among the top 10 of all time.

Arlington Capital Partners (“Arlington” or the “Firm”), a Washington, D.C. area based private equity investment firm focused on government-regulated sectors, today announced that it has successfully raised its latest fund, Arlington Capital Partners V, L.P. (“Fund V” or the “Fund”) with total capital commitments of approximately $1.7 billion – hitting the Fund’s hard cap. The fundraise, which was significantly oversubscribed, successfully reached its final closing in three months from its launch. The Fund sourced capital commitments from a hand-selected, globally diverse group of marquis investors, including public pension funds, corporate pension funds, insurance companies, fund of funds, and foundations.

The University of Maryland, Baltimore plans an ambitious expansion of its BioPark, with a $200 million building that will nearly double the size of the life science hub to the west of the main medical campus downtown.

Sometimes a Eureka moment sparks a breakthrough in innovation; other times it’s a rush to solve a crisis plaguing society — and the ones you love. That was the case for Martine Rothblatt, CEO of United Therapeutics, a Maryland-based company she founded in 1996, and former CEO of GeoStar and creator of SiriusXM Radio.

The days of Roche having an immunotherapy monopoly on the largest population of small-cell lung cancer patients appear numbered, following the release of data for a competing drug.

If biopharma firms want to get the most out of continuous manufacturing, they must rethink their viral safety strategies. Existing strategies work well for batch-mode production, as hard-won experience attests. These strategies, however, are still being adapted to continuous-mode production, where protocols and equipment preferences are in flux.

By Dr. Kurt Newman, CEO of Children’s National Health System

We have come a long way in pediatric medicine, but not far enough.

For nearly a decade, the chief executives of the nation's children's hospitals and health systems have discussed challenges we face in caring for America's very sickest children, whose life-threatening diseases and congenital conditions put overwhelming burdens on their families.

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and manufacturing partner for gene therapies, today announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to state-of-the-art manufacturing equipment, people and space to accelerate the growth of its gene therapy development and manufacturing business.

The University of Maryland School of Pharmacy has launched the nation's first Master of Science program in medical cannabis science and therapeutics.

The university says the degree will provide students with the knowledge and skills needed to support patients and the medical cannabis industry.

As the dominant economic geography of America, metropolitan statistical areas largely determine our success as a nation. These groups of counties with a large central core account for 88.6 percent of jobs, 89.1 percent of wages and 90.0 percent of Gross Domestic Product (GDP). Further, metropolitan statistical areas account for the bulk of innovation such as research and development and patenting activity. Understanding the mechanisms underpinning the growth of top-performing metropolitan areas, and sharing best practices, could assist other communities in boosting their economic fortunes. The Most Dynamic Metropolitan Index, ranking 379 metropolitan areas, seeks to provide an objective measure of the economic vibrancy of communities where the lion’s share of Americans work and live.

Adaptive Biotechnologies has raised the price for its initial public offering, putting itself in a position to raise more cash than any other biotech IPO this year. The Seattle-based company, which makes technology that can read the genetic information of the human immune system, increased its target price to $18 to $19 per share and could raise as much as $327.5 million from investors, according to a new SEC filing.

Health Tech early stage (below $10 million) investing grew consistently from 2010 - 2017, but then stalled in 2018 showing declining deal count in every quarter over the previous year. At the same time, total capital invested was flat. Was it a correction?

Results from Q1 2019 show the segment is back on the growth track. Deal counts won’t yet match 2016 and 2017 levels, but they will be up from 2018 and capital invested in U.S. early stage health tech is likely to be the highest on record.

The company that makes Botox is the subject of the latest biopharma mega-deal.

Chicago-based AbbVie said Tuesday it would acquire Ireland-headquartered Allergan for $63 billion, or $78.45 per share, equal to the former’s Monday closing price. The companies said the deal would provide immediate scale and profitability for AbbVie while allowing the company to diversify into new therapeutic areas like aesthetics.

At the end of November in Washington, D.C., Children's National Health System began work on a historical renovation construction project that will result in a pediatric research and innovation campus with a focus on pediatric medicine.